REDWOOD CITY, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the H.C. Wainwright Global Investment Conference, being held May 23-26, 2022, virtually and in Miami, FL.
The presentation will be available on-demand beginning at 7 AM Eastern Time on Tuesday, May 24, 2022 in the Investors section on the Company’s website at www.soleno.life .
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life .
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578